Cogent Biosciences, Inc. (as identified in request) — 2019 Q1 10-Q summary
Issuer discrepancy: The filing is for Unum Therapeutics Inc., not Cogent Biosciences, Inc. Investors should confirm that this is the intended filing. Reporting period ended March 31, 2019; financial statements are unaudited. Amounts below are in U.S. dollars.
Business context and reporting period
Unum was a clinical-stage biopharmaceutical company developing ACTR engineered T-cell therapies and its BOXR platform. It had no products approved for sale and no product-sales revenue. Its reported collaboration revenue came from its Seattle Genetics collaboration.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 or comparison |
|---|---|---|
| Collaboration revenue | $3.053 million | $2.220 million |
| Research and development expense | $12.403 million | $8.142 million |
| General and administrative expense | $2.491 million | $1.064 million |
| Total operating expenses | $14.894 million | $9.206 million |
| Operating loss | $11.841 million | $6.986 million |
| Net loss | $11.691 million | $6.735 million |
| Basic and diluted loss per share | $0.39 | $0.66 |
| Cash used in operating activities | $11.518 million | $7.981 million |
At March 31, 2019, cash and cash equivalents were $59.114 million and marketable securities were $7.989 million, totaling $67.103 million. Total current assets were $69.900 million versus current liabilities of $26.345 million. Stockholders’ equity was $49.290 million. The balance sheet included $7.152 million of operating lease liabilities. No term-loan borrowings were outstanding; up to $15 million was available under the amended loan agreement. The filing reports no other conventional debt balance.
Changes versus prior comparable period
- Revenue increased $0.833 million, primarily reflecting increased activity under the Seattle Genetics collaboration.
- R&D expense rose $4.261 million, with higher clinical-trial, manufacturing, personnel, and facility costs. G&A expense increased $1.427 million, primarily from public-company professional fees and higher personnel and insurance costs.
- Net loss increased $4.956 million. Loss per share decreased from $0.66 to $0.39, while weighted-average shares rose from about 10.2 million to 30.1 million, reflecting the post-IPO share base.
- Operating cash use increased $3.537 million. Cash, cash equivalents, and restricted cash nevertheless rose $3.443 million, principally because $14.992 million of marketable securities matured or were sold; this was a shift in investments, not operating cash generation.
Outlook, commentary, risks, and unusual items
- Management expected cash, cash equivalents, and marketable securities to fund operations and capital expenditure requirements into early 2021, excluding available loan borrowings. The notes also state that resources were expected to cover at least 12 months from the May 13, 2019 financial-statement issuance date. Management cautioned that estimates rely on assumptions and capital could be used sooner.
- Management expected continuing operating losses and increased expenses as clinical and preclinical programs advanced. Additional financing may be needed; equity issuance could dilute holders, while collaborations or licensing could require surrendering valuable rights.
- Clinical plans included continued dose escalation in the ACTR707/rituximab ATTCK-20-03 trial, planned cohort expansion in the second half of 2019, reporting ATTCK-20-2 data by year-end, continued ACTR087/SEA-BCMA dose escalation with data expected in the second half, and initial ACTR707/trastuzumab data expected at year-end. BOXR1030 remained in preclinical development.
- The Seattle Genetics agreement covered two ACTR programs through Phase I; $16.9 million of collaboration revenue was deferred at quarter-end. Approximately $51.0 million allocated to remaining performance obligations was expected to be recognized through December 31, 2022.
- In April 2019, the company filed a shelf registration allowing up to $150 million of securities and entered an at-the-market sales agreement for up to $50 million of common stock, with a 3% sales commission. The filing does not report that shares had been sold under this agreement.
- Other commitments included $3.6 million of non-cancelable manufacturing purchase commitments over the following 12 months and an operating lease expiring in April 2023. The company reported no material legal proceedings and no material changes to previously disclosed risk factors.
- Key risks include clinical and regulatory outcomes, manufacturing and supplier dependence, intellectual-property protection, collaboration performance, and the ability to obtain additional funding. The loan agreement is secured by substantially all assets other than intellectual property and includes affirmative and negative covenants.
Important facts for investors to verify
- Confirm the issuer: this document identifies Unum Therapeutics Inc., despite the request naming Cogent Biosciences, Inc.
- Verify current cash runway against actual spending, clinical-trial costs, financing activity, and any subsequent use of the $50 million ATM or $150 million shelf registration.
- Track clinical enrollment, safety, efficacy, dose-selection, and timing updates for the ACTR programs and progress of BOXR1030.
- Assess the assumptions behind collaboration revenue recognition and the expected timing of the remaining $51.0 million performance obligation.
- Review loan availability, amendment conditions, covenants, collateral, and manufacturing and lease commitments.